ERBB2 and neuroblastoma: In this regard, we compare the effect of Hsp70 or Hsp90 inhibition in HeLa and other clinically relevant human cancer cells including brain glioblastoma (U87 MG), neuroblastoma (SK-N-BE(2)-M17), triple negative (ER-, PR-, Her2-) breast adenocarcinoma (MSA-231), and estrogen responsive (ER+, PR+, Her2−) breast adenocarcinoma (MCF7) (Figure S5).